Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome

• Published in: Internal and emergency medicine Vol. 12; no. 1; pp. 1 - 7
• Main Authors: Sciascia, Savino, Radin, Massimo, Bazzan, Mario, Roccatello, Dario
• Format: Journal Article Book Review
• Language: English
• Published: Milan Springer Milan 01-02-2017; Springer Nature B.V
• Subjects: Adult; Antibodies, Anticardiolipin - analysis; Antibodies, Anticardiolipin - blood; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Anticoagulants - pharmacology; Anticoagulants - therapeutic use; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - therapy; beta 2-Glycoprotein I - analysis; beta 2-Glycoprotein I - blood; Female; Fibrinolytic Agents - pharmacology; Fibrinolytic Agents - therapeutic use; Humans; Hydroxychloroquine - pharmacology; Hydroxychloroquine - therapeutic use; Internal Medicine; Lupus Coagulation Inhibitor - analysis; Lupus Coagulation Inhibitor - blood; Medicine; Medicine & Public Health; Points of View; Pregnancy; Pregnancy Complications - diagnosis; Pregnancy Complications - prevention & control; Pregnancy Complications - therapy; Risk Assessment - methods; Rivaroxaban - pharmacology; Rivaroxaban - therapeutic use; Thrombosis - diagnosis; Thrombosis - therapy; Pregnancy morbidity; APS; aPL; Thrombosis
• ISSN: 1828-0447; 1970-9366
• DOI: 10.1007/s11739-016-1596-2

The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.